Jpn J Clin Oncol. May 9, 2022: hyac078. doi: 10.1093/jjco/hyac078. Online ahead of print.

ABSTRACT

OBJECTIVE: The aim of this study was to investigate the efficacy and safety of tranexamic acid in patients undergoing surgery for bone and soft tissue tumors.

METHODS: Data were collected retrospectively from 454 consecutive patients with bone and soft tissue tumors who underwent open biopsy, marginal resection, curettage, or wide resection between January 2017 and December 2018. We performed a propensity score matching of patients who received tranexamic acid with those who did not. The primary outcome variables were intraoperative, perioperative, and estimated blood loss (IBL, PBL, and EBL, respectively).

RESULTS: Tranexamic acid (+) and tranexamic acid (-) groups were defined according to whether or not patients received tranexamic acid. Of the 454 patients, open biopsy was performed in 102, marginal resection in 175, curettage in 54, and wide resection in 123. Intraoperative blood loss was significantly lower in the tranexamic acid (+) group than in the the tranexamic acid (-) group for marginal and wide resection (marginal resection: 17.3 vs. 70.3 g, respectively, P = 0.045; wide resection: 128.8 vs. 273.1 g, respectively, P = 0.023 ). Perioperative blood loss and estimated blood loss were also significantly lower in the tranexamic acid (+) group for wide resection (perioperative blood loss: 341.5 vs. 686.5 g, respectively, P = 0.0039; estimated blood loss: 320.7 versus 550.6 ml, respectively, P = 0.030). No venous thromboembolism occurred in either group.

CONCLUSION: This study suggests that the administration of TXA effectively and safely reduces blood loss, especially for wide resections, without increasing the rate of adverse events.

PMID:35532289 | DOI: 10.1093/jjco/hyac078